文献速递认知障碍与痴呆

脑脊液阿尔茨海默病生物标志物:与轻度认知障碍症状发作的时间变化关系及与年龄、性别和ApoE4的关联

CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4.
PubMed 文献 · Neurology · 2022-01-01

基于BIOCARD队列273名基线认知正常者(平均随访16年,94人进展为轻度认知障碍),发现基线脑脊液ptau181和t-tau升高与7年内症状发作相关,而Aβ42/Aβ40比值降低与7年后症状发作相关;这些关联在男性中强于女性,且性别差异随年龄增长而减弱。

要点

  • 基线脑脊液ptau181和t-tau升高与7年内轻度认知障碍症状发作相关。
  • 基线脑脊液Aβ42/Aβ40比值降低与7年后轻度认知障碍症状发作相关。
  • 生物标志物与轻度认知障碍进展的关联在男性中强于女性,性别差异随年龄增长而减弱。

核心结论

  • 基线脑脊液ptau181和t-tau升高与7年内轻度认知障碍症状发作相关,Aβ42/Aβ40比值降低与7年后症状发作相关,且这些关联受年龄和性别影响。

研究设计与样本

  • 研究为正在进行的纵向项目BIOCARD队列,纳入273名基线认知正常且主要为中年人的参与者,平均随访16年(最长23.6年)。
  • 采用全自动Lumipulse G免疫分析法检测基线脑脊液淀粉样蛋白(Aβ1-42和Aβ1-40)、磷酸化tau(ptau181)和总tau(t-tau)。
  • 使用Cox回归模型分析基线生物标志物水平与轻度认知障碍症状发作时间的关系,并检验与年龄、性别和ApoE等位基因状态的交互作用。

主要发现

  • 随访期间94人进展为轻度认知障碍,中位症状发作时间为6.9年。
  • 在Cox回归模型中,基线ptau181升高与7年内轻度认知障碍症状发作相关(HR 1.386,p=0.009),基线t-tau升高与7年内症状发作相关(HR 1.329,p=0.017)。
  • 基线Aβ42/Aβ40比值降低与7年后轻度认知障碍症状发作相关(HR 0.596,p=0.003)。
  • ptau181和Aβ42/Aβ40存在显著的脑脊液×年龄×性别三阶交互作用,随访分析表明这些生物标志物与轻度认知障碍进展的关联在男性中强于女性,但性别差异随年龄增长而减弱。

临床怎么用

  • 作者认为这些因素可能为临床试验入组策略、试验时长和结局提供参考,这些试验可能使用上述指标作为治疗反应的替代标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: This study aimed to examine whether baseline CSF measures of Alzheimer disease (AD)-related pathology are associated with the time to onset of mild cognitive impairment (MCI) and whether these associations differ by age, sex, Apolipoprotein E (ApoE4) status, and proximal (≤7 years) vs distal (>7 years) time to symptom onset. METHODS: Measures of amyloid (Aβ1-42 and Aβ1-40), phospho-tau (ptau181), and total tau (t-tau) were determined from CSF samples obtained at baseline from participants in an ongoing longitudinal project, known as the Biomarkers for Older Controls at Risk for Alzheimer Disease study (BIOCARD) study. The fully automated, Lumipulse G immunoassay was used to analyze the specimens. Cox regression models were used to examine the relationship of baseline biomarker levels with time to symptom onset of MCI and interactions with age, sex, and ApoE allelic status in subjects who progressed from normal cognition to MCI. RESULTS: Analyses included 273 participants from the BIOCARD cohort, who were cognitively normal and predominantly middle-aged at baseline, and have been followed for an average of 16 years (max = 23.6). During follow-up, 94 progressed to MCI (median time to symptom onset = 6.9 years). In Cox regression models, elevated ptau181 and t-tau levels were associated with time to MCI symptom onset if it occurred within 7 years of baseline (HR 1.386 and 1.329; p = 0.009 and 0.017, respectively), while a lower Aβ42/Aβ40 ratio was associated with symptom onset if it occurred >7 years from baseline (HR 0.596, p = 0.003). There were also significant 3-way CSF × age × sex interactions for ptau181 and Aβ42/Aβ40, with follow-up analyses indicating that associations between these biomarkers and progression to MCI were stronger among men than among women, but this difference between sexes diminished with increasing age. DISCUSSION: The lengthy follow-up of BIOCARD participants permitted an examination of time-varying associations between CSF AD biomarkers with MCI symptom onset and the influence of sex, baseline age, and ApoE4 genotype on these associations. These factors may inform clinical trial enrollment strategies, or trial duration and outcomes, which may use these measures as surrogate markers of treatment response.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Greenberg BD, Pettigrew C, Soldan A, et al. CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4. Neurology. 2022. PMID: 36216518. doi:10.1212/WNL.0000000000200953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。